Goldsmith Mark A

See Remarks, DirectorRevolution Medicines, Inc. (RVMD) · full profile →Form 4 · filed Mar 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.6M
Net Open-Market Flow
-$3.6M
Transactions
17
15 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Sell(S)4K$100.73$365K312K
Mar 2, 2026Sell(S)21K$101.60$2.2M290K
Mar 2, 2026Sell(S)700$98.17$69K319K
Mar 2, 2026Option exercise(M)30K$4.09$123K320K
Mar 2, 2026Sell(S)851$102.20$87K290K
Mar 2, 2026Sell(S)100$98.31$10K67K
Mar 2, 2026Sell(S)400$100.12$40K67K
Mar 2, 2026Sell(S)2K$101.47$172K65K
Mar 2, 2026Sell(S)800$102.00$82K64K
Mar 2, 2026Sell(S)100$98.29$10K67K
Mar 2, 2026Sell(S)600$100.19$60K67K
Mar 2, 2026Sell(S)2K$101.63$213K65K
Mar 2, 2026Sell(S)200$102.08$20K64K
Mar 2, 2026Sell(S)4K$99.76$349K315K
Mar 1, 2026Grant(A)57K$0290K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2026Option exercise(M)30K$048K
Mar 1, 2026Grant(A)129K$0129K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-26-000082) within minutes of acceptance. Every field above traces to the original document. Verify it directly: